Published in Nat Med on October 05, 2003
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 2.83
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol (2006) 2.09
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (2004) 1.99
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother (2005) 1.91
Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes. Immunity (2015) 1.91
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med (2007) 1.73
Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol (2007) 1.67
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res (2013) 1.60
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. J Leukoc Biol (2013) 1.45
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A (2005) 1.36
Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood (2008) 1.34
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26
Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26
Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog (2009) 1.26
Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol (2010) 1.26
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood (2006) 1.25
Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23
Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol (2009) 1.20
New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines (2010) 1.18
Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood (2009) 1.18
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog (2013) 1.16
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. J Immunol Methods (2007) 1.14
Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood (2008) 1.12
Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol (2005) 1.12
γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One (2011) 1.11
Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol (2010) 1.11
The level of friend retrovirus replication determines the cytolytic pathway of CD8+ T-cell-mediated pathogen control. J Virol (2007) 1.10
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol (2007) 1.10
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Retrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-I-associated neurologic disease. Blood (2008) 1.07
Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun (2006) 1.06
Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res (2009) 1.06
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS (2010) 1.03
Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant (2010) 1.00
Protein kinase Cdelta regulates antigen receptor-induced lytic granule polarization in mouse CD8+ CTL. J Immunol (2007) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A (2010) 0.96
CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J Immunol (2008) 0.95
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods (2007) 0.95
Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol (2007) 0.95
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology (2015) 0.94
DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol (2012) 0.94
A practical approach to T-cell receptor cloning and expression. PLoS One (2011) 0.93
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res (2010) 0.93
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep (2016) 0.93
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. J Immunol (2008) 0.93
Isolation of viable antigen-specific CD8+ T cells based on membrane-bound tumor necrosis factor (TNF)-α expression. J Immunol Methods (2011) 0.93
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol (2007) 0.92
Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92
Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol (2005) 0.92
Exocytic responses of single leukaemic human cytotoxic T lymphocytes stimulated by agents that bypass the T cell receptor. J Physiol (2005) 0.92
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation (2008) 0.91
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res (2005) 0.91
Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells. PLoS One (2013) 0.88
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine (2010) 0.88
Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J Clin Immunol (2006) 0.88
Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol (2008) 0.87
Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol (2005) 0.87
Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J Immunol (2008) 0.87
Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200. J Virol (2012) 0.86
Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol (2013) 0.85
Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med (2004) 0.85
Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother (2014) 0.83
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
Generation of functional, antigen-specific CD8+ human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling. Stem Cells (2014) 0.82
Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PLoS Pathog (2008) 0.82
Reduced degranulation of NK cells in patients with frequently recurring herpes. Clin Vaccine Immunol (2011) 0.82
Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology (2013) 0.82
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep (2014) 0.81
Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med (2011) 0.81
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother (2009) 0.80
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol (2004) 7.37
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med (2006) 4.41
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 3.58
A new "Logicle" display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytometry A (2006) 3.49
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Quality assurance for polychromatic flow cytometry. Nat Protoc (2006) 3.34
Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods (2006) 3.32
Vaccination in humans generates broad T cell cytokine responses. J Immunol (2004) 3.27
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 3.26
Core competencies for pain management: results of an interprofessional consensus summit. Pain Med (2013) 3.25
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
A deep profiler's guide to cytometry. Trends Immunol (2012) 3.14
A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol (2002) 3.07
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Intracellular cytokine optimization and standard operating procedure. Nat Protoc (2006) 2.96
SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood (2007) 2.95
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med (2005) 2.83
The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem (2002) 2.71
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med (2006) 2.70
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol (2007) 2.67
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat Immunol (2002) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Role of BCR affinity in T cell dependent antibody responses in vivo. Nat Immunol (2002) 2.63
HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A (2005) 2.61
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med (2004) 2.59
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest (2012) 2.55
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol (2008) 2.44
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol (2002) 2.44
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol (2003) 2.34
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Data analysis in flow cytometry: the future just started. Cytometry A (2010) 2.18
A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology (2008) 2.17
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
Optimizing a multicolor immunophenotyping assay. Clin Lab Med (2007) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol (2011) 2.10
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med (2009) 2.10
Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol (2006) 2.09
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med (2010) 2.07
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood (2012) 2.03
Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03
The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol (2004) 2.01
Beyond six colors: a new era in flow cytometry. Nat Med (2003) 1.94
Data exploration, quality control and testing in single-cell qPCR-based gene expression experiments. Bioinformatics (2012) 1.93
T-cell therapy at the threshold. Nat Biotechnol (2012) 1.91
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med (2007) 1.89
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88